1 October 2020 - Pfizer today announced that its investigational gene therapy candidate (PF-06939926) being developed to treat Duchenne muscular dystrophy received fast track designation from the U.S. FDA.
PF-06939926 is currently being evaluated to determine the safety and efficacy of this gene therapy in boys with Duchenne muscular dystrophy.